Jurij Zdovc (Avtor), Jurij Hanžel (Avtor), Tina Kurent (Avtor), Nejc Sever (Avtor), Matic Koželj (Avtor), Nataša Smrekar (Avtor), Gregor Novak (Avtor), Borut Štabuc (Avtor), Tomaž Vovk (Avtor), Barbara Ostanek (Avtor), David Drobne (Avtor), Iztok Grabnar (Avtor)

Povzetek

Ustekinumab is a monoclonal antibody used in Crohn's disease (CD). Dose optimization in case of non-response and the role of pharmacokinetic-pharmacodynamic (PK-PD) monitoring remain unresolved dilemmas in clinical practice. We aimed to develop a population PK-PD model for ustekinumab in CD and simulate efficacy of alternative dosing regimens. We included 57 patients and recorded their characteristics during 32 weeks after starting with ustekinumab therapy. Serum ustekinumab concentration was prospectively measured and fecal calprotectin (FC) concentration was used to monitor the disease activity. Ustekinumab PK-PD was described by a two-compartment target-mediated drug disposition model linked to an indirect response model. Lower fat-free mass, higher serum albumin, previous non-exposure to biologics, FCGR3A-158 V/V variant and lower C-reactive protein were associated with higher ustekinumab exposure. Model-based simulation suggested that 41.9% of patients receiving standard dosing achieve biochemical remission at week 32. In patients not achieving remission with standard dosing at week 16, transition to 4-weekly subcutaneous maintenance dosing with or without intravenous reinduction resulted in comparably higher remission rates at week 32 (51.1% vs. 49.2%, respectively). Our findings could be used to guide stratified ustekinumab treatment in CD, particularly in patients with unfavorable characteristics, who might benefit from early transition to 4-weekly maintenance dosing.

Ključne besede

vnetje črevesja;terapevtsko spremljanje zdravil;fekalni kalprotektin;ustekinumab;inflammatory bowel disease;fecal calprotectin;pharmacokinetics-pharmacodynamics;therapeutic drug monitoring;

Podatki

Jezik: Angleški jezik
Leto izida:
Tipologija: 1.01 - Izvirni znanstveni članek
Organizacija: UL FFA - Fakulteta za farmacijo
UDK: 615.277.3:616.344-002
COBISS: 78625027 Povezava se bo odprla v novem oknu
ISSN: 1999-4923
Št. ogledov: 122
Št. prenosov: 55
Ocena: 0 (0 glasov)
Metapodatki: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Ostali podatki

Sekundarni jezik: Slovenski jezik
Sekundarne ključne besede: Crohnova bolezen;Tarčna zdravila;
Vrsta dela (COBISS): Članek v reviji
Strani: str. 1-16
Letnik: ǂVol. ǂ13
Zvezek: ǂiss. ǂ10
Čas izdaje: 2021
DOI: 10.3390/pharmaceutics13101587
ID: 15107989